Massachusetts Financial Services Co. MA Raises Position in Ascendis Pharma A/S (NASDAQ:ASND)

Massachusetts Financial Services Co. MA grew its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 5.8% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,711,015 shares of the biotechnology company’s stock after purchasing an additional 93,185 shares during the quarter. Massachusetts Financial Services Co. MA owned approximately 2.94% of Ascendis Pharma A/S worth $233,348,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Westfield Capital Management Co. LP raised its position in shares of Ascendis Pharma A/S by 1.1% in the 1st quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company’s stock worth $616,050,000 after buying an additional 44,580 shares during the period. Avoro Capital Advisors LLC raised its position in shares of Ascendis Pharma A/S by 5.6% in the 1st quarter. Avoro Capital Advisors LLC now owns 3,966,666 shares of the biotechnology company’s stock worth $599,641,000 after buying an additional 211,111 shares during the period. Capital International Investors raised its position in shares of Ascendis Pharma A/S by 0.5% in the 1st quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock worth $331,261,000 after buying an additional 10,044 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Ascendis Pharma A/S by 23.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after buying an additional 336,976 shares during the period. Finally, Vestal Point Capital LP purchased a new position in shares of Ascendis Pharma A/S in the 4th quarter worth $78,719,000.

Analysts Set New Price Targets

Several brokerages recently weighed in on ASND. The Goldman Sachs Group increased their target price on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday. JPMorgan Chase & Co. lowered their price target on Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating for the company in a report on Wednesday, September 4th. Jefferies Financial Group increased their price target on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a report on Tuesday, August 13th. Wells Fargo & Company increased their price target on Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Citigroup increased their price target on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $193.77.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $146.59 on Wednesday. Ascendis Pharma A/S has a one year low of $85.29 and a one year high of $161.00. The company has a 50-day simple moving average of $132.51 and a 200-day simple moving average of $136.47. The firm has a market capitalization of $8.54 billion, a PE ratio of -15.25 and a beta of 0.63.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.